Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Feb 04, 2022 3:34pm
281 Views
Post# 34399191

Food for thought

Food for thoughtJP Morgan recently had their big healthcare conference and TH utilized that to have meetings with analysts, bankers and potential partners. JPM recently picked up coverage of BGNE with a 65 page report. Paul reported to shareholders he was meeting with that TH had a growing relationship with JPM and a JPM banker did something (I can't remember exactly what) on TH's LinkedIn site. TH wished people a Happy Chinese New Year for the first time ever on their LinkedIn site and Paul is following BGNE on LinkedIn. JPM was one of the underwriters of BGNE's recent offering on 12/15/21.

Could there be something more signinficant on the horizon than just a partership between BGNE and TH? Probably not but there are signs that a lot of talking is going on among these three entities and once you start talking you never know where it might lead. You know JPM would be keen to get something going where they earn a nice fee. TH could sell a stake in TH to BGNE to fund NASH and/or finance the potential redemption of the convert? 

There is likely nothing there but where there is smoke there has to be a fire.  
<< Previous
Bullboard Posts
Next >>